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Excessive fuel availability amplifies 
the FTO-mediated obesity 
risk: results from the TUEF and 
Whitehall II studies
Róbert Wagner  1,2,3, Ádám G. Tabák4,5, Ellen Fehlert1,2,3, Louise Fritsche1,2,3, Benjamin A. 
Jaghutriz1,2,3, Róbert J. Bánhegyi6, Sebastian M. Schmid3,7, Harald Staiger2,3,8,9,10, Fausto 
Machicao10, Andreas Peter1,2,3, Hans-Ulrich Häring1,2,3, Andreas Fritsche1,2,3 & Martin Heni  1,2,3
Variation in FTO is the most important common genetic determinant of body weight. Altered energy 
metabolism could underlie this association. We hypothesized that higher circulating glucose or 
triglycerides can amplify the FTO impact on BMI. In 2671 subjects of the TUEF study, we investigated 
the interaction effect of fasting glucose and triglyceride levels with rs9939609 in FTO on BMI. We 
analysed the same interaction effect by longitudinally utilizing mixed effect models in the prospective 
Whitehall II study. In TUEF, we detected an interaction effect between fasting glucose and fasting 
triglycerides with rs9939609 on BMI (p = 0.0005 and p = 5 × 10−7, respectively). The effect size of one 
risk allele was 1.4 ± 0.3 vs. 2.2 ± 0.44 kg/m² in persons with fasting glucose levels below and above 
the median, respectively. Fasting triglycerides above the median increased the per-allele effect from 
1.4 ± 0.3 to 1.7 ± 0.4 kg/m2. In the Whitehall II study, body weight increased by 2.96 ± 6.5 kg during 
a follow-up of 13.5 ± 4.6 yrs. Baseline fasting glucose and rs9939609 interacted on weight change 
(p = 0.009). Higher fasting glucose levels may amplify obesity-risk in FTO carriers and lead to an 
exaggerated weight gain over time. Since weight gain perpetuates metabolic alterations, this interplay 
may trigger a vicious circle that leads to obesity and diabetes.
Due to its increasing global prevalence, obesity has become a major health problem worldwide. Since it is strongly 
linked to insulin resistance, obesity increases the disease burden of type 2 diabetes. The pathogenesis of obesity 
comprises an intricate interplay of genetic and environmental factors. For the genetic contribution, around a 
hundred single nucleotide polymorphisms (SNPs) are reported to be associated with BMI1. However, the aggre-
gate influence of these known variants explains the heritability of obesity to a small extent (~2.7%) only1. Genetic 
effects can show striking variation, depending on the metabolic environment which, in turn, reflects lifestyle or 
other genetic factors. Interactions between environmental factors and genetic loci might therefore account for 
some of the variability2. The impact of the common genetic variant in FTO, the polymorphism most strongly 
and consistently associated with obesity, is modulated by such factors. Physical activity, aerobic fitness, and diet 
interact with the FTO variant on obesity or the change of body weight over time3–6. For other diabetes-related 
genetic variants, such as TCF7L2, glycemia is an important interacting factor modulating the SNP’s effect7. We 
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have already demonstrated that the risk allele of FTO is associated with higher food intake8, altered processing of 
food signals in the brain9 and with insulin resistance of the human brain10. Recent data suggest that the variation 
in FTO also has an impact on the transcription factors that regulate adipocyte development11. Indeed, adipocytes 
from FTO risk allele carriers have an altered energy homeostasis: they store energy more efficiently and pro-
duce less excess heat11. We thus hypothesized that higher plasma levels of energy substrates, namely glucose and 
triglycerides, could intensify this increased lipid storage, thereby causing excessive weight gain, particularly in 
subjects carrying the risk allele in FTO.
Methods
All methods were performed in accordance with the relevant guidelines and regulations.
Subjects. TUEFF. The Tübingen Family Study for type 2 diabetes (TUEF) is designed to establish a thor-
oughly phenotyped cohort of a population at increased risk of type 2 diabetes. To this end, subjects with known 
prediabetes (without known diabetes), a family history of diabetes, or obesity are continuously recruited to eval-
uate metabolic status with respect to glucose and lipid metabolism. The Ethics Committee of the Medical Faculty 
of the University of Tübingen approved the study protocol. Written informed consent was obtained from all 
participating individuals. Further details on the study have already been published12.
Whitehall-II. Data from the occupational Whitehall II cohort were accessed by a data sharing agreement. 
Details of the study have already been published13. The study was approved by the Joint UCL/UCLH Committees 
on the Ethics of Human Research (Committee Alpha). All participants provided written informed consent. The 
Whitehall II study was initiated in 1985 and recruited 10,308 participants (3,413 women) aged 35–55 years with 
a response rate of 73% from 20 London based Civil Service departments. The initial visit (phase 1) included a 
clinical examination and a self-administered questionnaire in 1985–88. During follow-up, 5-yearly clinical exam-
inations were performed (Phase 3: 1991–94, Phase 5: 1997–99, Phase 7: 2002–04, and Phase 9: 2007–09) and 
additional postal questionnaire only phases were conducted (Phase 2:1988–90, Phase 4: 1995–96, Phase 6: 2001, 
and Phase 8: 2006). As 75 g oral glucose tolerance tests (OGTT) were first performed in phase 3, this provides the 
baseline for the current analysis. Disclosed data was available for 5067 white participants for phases 3, 5, 7 and 
9, amounting to a total of 24,029 person-examinations. After removing missing or non-fasted glucose measure-
ments14, missing weight or genotyping information and participants with known diabetes, we gained a full dataset 
comprising 16,307 person-examinations.
Oral glucose tolerance test (OGTT) and laboratory analyses. In the TUEF study, all participants received a 75-g 
glucose solution (Accu-Check Dextro, Roche) at 8 a.m. following an overnight fast. Venous blood was obtained 
through an indwelling venous catheter before and 30, 60, 90 and 120 minutes after glucose ingestion. The proce-
dure of OGTT in the Whitehall II study was already described in detail14.
Glucose was analysed in both the TUEF and the Whitehall II study using an YSI glucose analyser (Yellow 
Springs Instruments).
Fasting triglyceride concentrations were measured by a standard colorimetric method on a Bayer analyser (Bayer 
HealthCare) in TUEF, and by a Cobas Fara centrifugal analyser (Roche Diagnostics System) in Whitehall II15.
Genotyping. Following appropriate cell lysis, protein precipitation and washing in the TUEF study, the SNP 
rs9939609 was genotyped from blood samples using the MassARRAY platform (Sequenom). Genotyping of 
Whitehall II participants was described earlier16.
Statistical analysis. Data are presented as median and interquartile range or mean ± SD. To determine whether 
glycemia or triglycerides modulate the effect of the SNP on body weight and BMI, linear regression modelling 
was performed with the least squares method, including the interaction term SNP × environmental factor. Age 
and sex were included as covariates in all linear regression models. From the linear regression models, the effect 
sizes are given as effect estimates (estimate). Records with missing data were excluded. The FTO SNP rs9939609 
genotype was modelled according to the additive inheritance model; the SNP variable indicating the number of 
risk alleles. Longitudinal data in the Whitehall II cohort was investigated by testing fold-change BMI between 
adjacent visits. Linear mixed models were fitted, adjusting for the random effects subject and time since the 
beginning of the study. Fixed effect variables comprised sex, BMI on the previous visit, age, age-squared, elapsed 
time between the observations, fasting glucose on the previous visit, and the genotype, with all interactions of 
the latter three variables. The analyses were performed with R 3.3.2 (R Core Team), using the lme4 package for 
mixed models.
Data availability statement. The dataset of the TUEF study is not publicly available due to ethical reasons 
concerning the participants’ informed consents, but is available from the corresponding author on appropriate 
request. The availability of the Whitehall-II data is subject to an individual data-sharing agreement.
Results
TUEF Study. Participants of the cross-sectional TUEF study (N = 2671) had a median BMI above 28 kg/m2, 
and the interquartile ranges indicated a high proportion of subjects with higher BMI (see Table 1). As anticipated, 
genetic variation in FTO was strongly associated with BMI (p = 1.7·10−10), even after adjusting for sex and age 
(p = 2.9·10−10). The effect size on BMI amounted to 1.7 ± 0.3 kg/m2 per risk allele. We fitted linear regression 
models to assess the impact of both glucose levels and plasma triglycerides on the association of the genetic 
variant in FTO with BMI. We tested the interaction terms between FTO × fasting glucose, FTO × post-chal-
lenge glucose and FTO × fasting plasma triglycerides on BMI. In all models, age and sex were included as 
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additional covariates. Genetic variation in FTO revealed significant interaction with fasting glucose in models 
with (p = 0.0005) and without (p = 0.003) additional adjustment for fasting plasma triglycerides. This translated 
to a 1.78 ± 0.73 kg/m2 higher BMI associated with each 1 mmol/l higher glucose value in the presence of the AA 
risk genotype than in the TT genotype. This interaction remained significant even after additional adjustment for 
insulin sensitivity (p = 0.003). In similar models, fasting plasma triglycerides showed interaction effects with FTO 
on BMI with (p = 5·10−7) and without (p = 0.0002) additional adjustment for fasting glucose. The presence of the 
AA risk genotype rather than the TT genotype implicated a 2.11 ± 0.51 kg/m2 higher BMI associated with each 
1 mmol/l higher triglyceride value. However, no interaction of FTO with post-challenge glucose was observed 
(p = 0.3) (see Fig. 1).
We next stratified the study population at the median of fasting glucose levels into low-glucose (<5.17 mmol/l) 
and high-glucose (≥5.17 mmol/l) groups. Genetic variation in FTO exhibited a lower effect size in the low-glucose 
group (estimate = 1.4 ± 0.3 kg/m2, p = 6·10−6) than in the high-glucose group (estimate = 2.2 ± 0.44 kg/m2, 
p = 6·10−7). A similar stratification was performed using low-triglyceride (<1.15 mmol/l) and high-triglyceride 
(≥1.15 mmol/l) groups. The impact of FTO on BMI was also lower in the low-triglyceride group (esti-
mate = 1.4 ± 0.3 kg/m2, p = 2·10−5) than in the high-triglyceride group (estimate = 1.7 ± 0.4 kg/m2, p = 2·10−5). 
All models were adjusted for sex, age, plasma triglycerides, and fasting glucose, respectively. The data are also 
shown in Fig. 2.
Whitehall II Study. In this longitudinal cohort, we tested whether fasting glucose and triglyceride concen-
trations modulate the impact of the FTO SNP on BMI over time. During the observation period of 13.5 ± 4.6 
years, the 4966 participants involved displayed a mean weight gain of 2.96 ± 6.5 kg, translating to a BMI change 
of 1.42 ± 2.2 kg/m2, i.e. a 5.7 ± 8.6% relative increase in BMI. BMI and diabetes incidence at the last observation, 
stratified by FTO genotypes, is provided in Supplementary Table 1. Using a linear mixed model, we modelled 
the BMI change between consecutive visits as a function of the FTO SNP and the fasting glucose levels assessed 
during the previous visit. The models also comprised the covariates sex, age, age-squared, and elapsed time since 
the last observation. Fasting glucose during the previous observation significantly interacted with FTO on BMI 
change (b = 0.002 ± 0.0008, p = 0.04, Supplementary Figure 1). This translates to a 0.2 percentage-points higher 
BMI increase per risk-allele for 1 mmol/l higher fasting glucose. We also ascertained an inversely directed sig-
nificant interaction between elapsed time since the last observation, fasting glucose in the last observation, and 
FTO (b = −0.0019 ± 0.0008, p = 0.02), suggesting that the interaction effect diminishes over time. No comparable 
interaction was evident for fasting plasma triglycerides (p = 0.6). Moreover, post-challenge glucose levels did not 
modulate the impact of genetic FTO variation on weight gain (p = 0.67). To allow for robust visualization of the 
data, we computed individual average fasting glucose levels over all available time points and stratified this vari-
able into quartiles. A comparison of the lowest and the highest mean fasting glucose quartiles showed that mean 
fasting glucose modulated the impact of the FTO genotype over the total observation period (p = 0.04). This is 
indicative of a progressively higher weight gain in subjects who have higher average fasting glucose levels and who 
are carriers of the FTO risk allele (see Fig. 3).
Discussion
In this study, we investigated whether plasma glucose or triglyceride levels modulate the effect of the 
BMI-associated genetic variant in FTO. In two independent study populations, we demonstrated that fasting 
glucose and FTO interact to increase BMI and weight change over time. This interaction effect was also observed 
in the cross-sectional TUEF population with a broad range of BMI. However, post-challenge glucose does not 
interact with FTO genotype to increase obesity.
Gene × environment interactions are proposed to contribute to substantial parts of the hitherto genetically 
unexplained heritability of metabolic traits such as obesity or diabetes17. A recent family-based study showed the 
presence of significant gene × environment interactions for BMI involving environmental factors such as sex, 
age, alcohol intake and other dietary habits18. While glycemia is also an outcome of genetic and environmental 
factors, it is nevertheless an important attribute of the metabolic environment which, in turn, modulates multiple 
cellular processes. We have already shown that glucose levels interact with what is to date the most important 
diabetes-associated common SNP in TCF7L2 to affect insulin secretion19.
Numerous biological mechanisms may underlie the interaction between glucose and FTO detected in 
this study. Recent research indicates that FTO variation has a profound effect on adipocyte energy handling 
via the transcription factors IRX3 and IRX511,20. Increased expression of these transcription factors leads to 
study TUEF (N = 2671) Whitehall II* (N = 4966)
weight (kg) 85 (70.7–103.4) 75.1 (67.2–83.2)
BMI (kg/m²) 28.5 (24.2–35.7) 24.8 (22.8–27.0)
sex distribution females 64% females 26%
age (years) 41 (30–52) 49.5 (45.0–55.7)
fasting glucose (mmol/l) 5.2 (4.8–5.6) 5.2 (4.9–5.5)
fasting triglycerides (mmol/l) 1.15 (0.8–1.7) 1.16 (0.8–1.7)
FTO rs9939609 genotypes (AA/AT/TT in % of all) 32/50/18 36/48/16
Table 1. Baseline data from the TUEF and Whitehall II* studies. Given are medians and interquartile ranges or 
percentage. *Whitehall II data are presented for participants in the first available phase.
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cell-autonomous changes during adipocyte development, causing a phenotype that is associated with increased 
lipid storage and reduced energy loss via thermogenesis11. Both circulating glucose and triglycerides are impor-
tant substrate resources for lipid storage in adipocytes. Adipocytes synthesize triglycerides from glucose through 
de novo lipogenesis21, while circulating triglycerides are hydrolysed by lipoprotein-lipase and then re-esterified 
to triglycerides within the adipocytes22.
Abundance of energy carriers might thus augment the impact of FTO genotype by increasing substrate supply. 
One might therefore expect basal energy expenditure to be lower in FTO risk allele carriers. Despite several stud-
ies on this topic, however, there is still no convincing evidence that FTO has any impact on energy expenditure in 
humans23. However, we and others have shown that FTO risk allele carriers have an increased caloric intake8. In 
line with this, there is growing evidence that variation in FTO, the gene with the highest expression in the central 
nervous system, has an impact on central nervous appetite regulation9,24,25 and brain insulin sensitivity10. These 
processes in the human brain may involve the central dopaminergic system since genetically determined dopa-
mine receptor density modulates FTO effects even further26,27. We speculate that insulin resistance and appetite 
dysregulation associated with the risk allele of FTO could also contribute to the observed shift in the glucose-BMI 
regression line, as shown in Fig. 1A, thus explaining this interaction. Elevated glucose levels are known to sup-
press appetite, induce satiety and reduce food intake28,29. Since the association of FTO variation with brain activity 
is more pronounced in the context of elevated glucose9, higher glucose levels may enhance the impact of FTO on 
body weight also via the brain.
Limitations of this work include the different study populations, different measurement methods and differ-
ences in OGTT conditions which could potentially reduce the comparability of the two studies. A longitudinal 
analysis was available in Whitehall II only. Furthermore, circulating glucose and triglycerides does not necessarily 
indicate cellular energy availability to a full extent.
Figure 1. Linear regression models plotting the predicted values of BMI against fasting glucose (A), post-
challenge glucose (B), and fasting plasma triglycerides (C) in interaction with the FTO SNP rs9939609 in the 
TUEF study. Colors indicate genotypes of rs9939609. The p-values are given for the respective interaction terms 
in models adjusted for sex, age, and either fasting triglycerides in panel A or fasting glucose in panel C.
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By demonstrating that glycemia and possibly also triglyceride levels interact with FTO to modulate body 
weight, our work provides additional evidence for the importance of gene × environment interactions in the 
pathogenesis of obesity. Although the underlying biological mechanism of this interaction cannot be eluci-
dated by our data, our findings fit well into the known biological context. Our data suggest that individuals with 
increased fasting glucose levels have an even higher risk for weight gain if the strongest common genetic variant 
in the FTO gene is present. Since weight gain is known to further accelerate metabolic deterioration, this interplay 
may result in a vicious circle and thus lead to a more pronounced obese state and promote diabetes risk. Effective 
pharmacological and non-pharmacological glucose-lowering strategies may therefore be required to boost weight 
loss, particularly in FTO risk-allele carriers suffering from prediabetes or diabetes.
Figure 2. Relationship of FTO rs9939609 genotypes and BMI in subgroups stratified at the medians of fasting 
triglycerides (low TG, high TG) and fasting glucose (low G, high G). BMI per genotype is shown in each 
stratum as least squares mean with standard error (adjusted for sex, age, and either fasting triglycerides (in 
the glucose strata) or fasting glucose (in the triglyceride strata). The linear regression estimate, slope (b) with 
corresponding p-value (p), is shown by dashed lines.
Figure 3. Interaction effect of glycemia and rs9939609 in FTO on change of body weight in the longitudinal 
Whitehall-II study (p = 0.04). Panels show participants carrying different FTO rs9939609 genotypes, colours 
indicate quartiles of average fasting glucose per subject over the full observation period (red: bottom quartile, 
fasting glucose 4.07–4.9 mmol/l, blue: top quartile, fasting glucose 5.44–16 mmol/l). Lines indicate linear fits per 
glucose quartile with 95% confidence intervals in the respective colours.
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